院前环境中感染性休克患者接受抗生素治疗联合血流动力学优化对30天死亡率的影响
这项回顾性多中心研究纳入2016年5月至2021年12月需院前移动重症监护单元(MICU)干预的感染性休克患者530例,采用逆概率治疗加权(IPTW)倾向评分法分析首小时内院前抗生素治疗(ABT)和院前阶段结束时平均动脉压(MAP)≥65 mmHg与30天死亡率的关系。结果显示30天总死亡率为31%;首小时内ABT与30天死亡率显著相关(RRa=0.14 [0.04-0.55]),首小时内ABT联合MAP≥65 mmHg的RRa=0.08 [0.02-0.37],首小时内ABT但院前结束时MAP<65 mmHg的RRa=0.75 [0.45-0.85]。首小时后接受院前ABT者30天死亡率也降低(RRa=0.87 [0.57-0.99]),而未接受ABT者30天死亡率升高(RRa=2.36 [1.89-2.95])。作者认为院前首小时内ABT和院前结束时MAP≥65 mmHg均与30天死亡率降低相关,需进一步前瞻性研究证实。
要点
- 院前感染性休克患者中,首小时内给予抗生素与30天死亡率降低显著相关(RRa=0.14 [0.04-0.55])。
- 首小时内抗生素联合院前阶段结束时MAP≥65 mmHg者30天死亡率降低更明显(RRa=0.08 [0.02-0.37])。
- 首小时内抗生素但院前结束时MAP<65 mmHg者30天死亡率也降低(RRa=0.75 [0.45-0.85])。
- 未接受院前抗生素者30天死亡率升高(RRa=2.36 [1.89-2.95]);首小时后接受抗生素者死亡率也降低(RRa=0.87 [0.57-0.99])。
- 530例中仅132例(25%)接受了院前抗生素,其中98例(74%)使用第三代头孢菌素。
适用人群与场景
- 2016年5月至2021年12月期间需要院前移动重症监护单元(MICU)干预的感染性休克患者,共530例,其中男性341例(64%),平均年龄69±15岁。
- 感染疑似来源:肺部43%、泌尿25%、消化道17%。
诊断标准与关键阈值
- 院前阶段结束时平均动脉压(MAP)≥65 mmHg为血流动力学优化目标。
处置流程与药物剂量
- 首小时内给予抗生素治疗(ABT);132例(25%)接受了院前ABT,其中98例(74%)使用第三代头孢菌素。
- 院前阶段结束时维持MAP≥65 mmHg。
研究设计与关键结果
- 回顾性多中心研究,纳入530例院前感染性休克患者,采用逆概率治疗加权(IPTW)倾向评分法分析。
- 30天总死亡率为31%。
- 首小时内ABT与30天死亡率显著相关:RRa=0.14 [0.04-0.55]。
- 首小时内ABT联合院前阶段结束时MAP≥65 mmHg:RRa=0.08 [0.02-0.37]。
- 首小时内ABT但院前阶段结束时MAP<65 mmHg:RRa=0.75 [0.45-0.85]。
- 首小时后接受院前ABT者30天死亡率降低:RRa=0.87 [0.57-0.99]。
- 未接受ABT者30天死亡率升高:RRa=2.36 [1.89-2.95]。
证据类型、等级与局限
- 证据类型:回顾性多中心研究。
- 局限:作者指出需进一步前瞻性研究证实这些初步结果。
对床旁实践的改变
- 作者认为院前首小时内给予抗生素和院前阶段结束时MAP≥65 mmHg均与感染性休克患者30天死亡率降低相关。
指南或共识出处
- 国际指南推荐在1小时内实施早期治疗、抗生素治疗和血流动力学优化(原文引用,未注明具体指南名称)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In order to reduce septic shock mortality, international guidelines recommend early treatment implementation, antibiotic therapy (ABT) and hemodynamic optimisation, within 1-h. This retrospective multicentric study aims to investigate the relationship between prehospital ABT delivered within 1st hour and mean blood pressure (MAP) ≥ 65 mmHg at the end of the prehospital stage, and 30-day mortality among patients with septic shock.
METHODS: From May 2016 to December 2021, patients with septic shock requiring pre-hospital Mobile Intensive Care Unit intervention (MICU) were retrospectively analysed. To assess the relationship between 30-day mortality and prehospital ABT delivered within 1st hour and/or MAP ≥ 65 mmHg at the end of the prehospital stage, Inverse Probability Treatment Weighting (IPTW) propensity score method was performed.
RESULTS: Among the 530 patients included, 341 were male gender (64%) with a mean age of 69 ± 15 years. One-hundred and thirty-two patients (25%) patients received prehospital ABT, among which 98 patients (74%) were treated with 3rd generation cephalosporin. Suspected pulmonary, urinary and digestive infections were the cause of sepsis in respectively 43%, 25% and 17%. The 30-day overall mortality was 31%. A significant association was observed between 30-day mortality rate and (i) ABT administration within the first hour: RRa = 0.14 [0.04-0.55], (ii) ABT administration within the first hour associated with a MAP ≥ 65 mmHg: RRa = 0.08 [0.02-0.37] and (iii) ABT administration within the first hour in the prehospital setting associated with a MAP < 65 mmHg at the end of the prehospital stage: RRa = 0.75 [0.45-0.85]. Patients who received prehospital ABT after the first hour have also a 30-day mortality rate decrease: RRa = 0.87 [0.57-0.99], whereas patients who did not received ABT had an increased 30-day mortality rate: RRa = 2.36 [1.89-2.95].
CONCLUSION: In this study, we showed that pre-hospital ABT within the first hour and MAP≥65 mmHg at the end of prehospital stage are both associated with 30-day mortality decrease among patients suffering from septic shock cared for by a MICU. Further prospective studies are needed to confirm these preliminary results.
参考来源
- Jouffroy R, Holub M, Gilbert B, et al. Influence of antibiotic therapy with hemodynamic optimization on 30-day mortality among septic shock patients cared for in the prehospital setting. Am J Emerg Med. 2023. PMID: 37995523. doi:10.1016/j.ajem.2023.11.014
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。